A case of Beh‡et's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab

被引：94

作者：

Hirano, Toru ^{[1
]}

Ohguro, Nobuyuki ^{[2
]}

Hohki, Satoshi ^{[3
]}

Hagihara, Keisuke ^{[1
]}

Shima, Yoshihito ^{[1
]}

Narazaki, Masashi ^{[1
]}

Ogata, Atsushi ^{[1
]}

Yoshizaki, Kazuyuki ^{[4
]}

Kumanogoh, Atsushi ^{[1
]}

Kishimoto, Tadamitsu ^{[5
]}

Tanaka, Toshio ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Med, Dept Resp Med Allergy & Rheumat Dis, Suita, Osaka 5650871, Japan

[2] Osaka Koseinenkin Hosp, Dept Ophthalmol, Osaka, Japan

[3] Toyama Univ, Dept Ophthalmol, Grad Sch Med & Pharmaceut Sci, Toyama 930, Japan

[4] Osaka Univ, Ctr Adv Sci & Innovat, Suita, Osaka 5650871, Japan

[5] Osaka Univ, Lab Immune Regulat, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan

来源：

MODERN RHEUMATOLOGY | 2012年 / 22卷 / 02期

关键词：

Behcet's disease; IL-6; Tocilizumab; GENOME-WIDE ASSOCIATION; BEHCETS-DISEASE; CEREBROSPINAL-FLUID; INTERLEUKIN-6; IL23R-IL12RB2; GENERATION; THERAPY; CELLS; IL10;

D O I：

10.1007/s10165-011-0497-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 47-year-old female patient with Beh double dagger et's disease had been treated with colchicine, prednisolone, cyclosporine A, and infliximab. Because she relapsed, however, treatment with tocilizumab, a humanized anti-interleukin 6 receptor antibody, was started. This treatment suppressed the patient's clinical manifestations, including ocular attacks, for 1 year and improved her visual acuity. This experience indicates that tocilizumab may constitute a therapeutic option for refractory Beh double dagger et's disease.

引用

页码：298 / 302

页数：5

共 24 条

[1] [Anonymous], 1987, CLASS CRIT BEHC DIS
[2] Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
Bettelli, E
Carrier, YJ
Gao, WD
Korn, T
Strom, TB
Oukka, M
Weiner, HL
Kuchroo, VK
[J]. NATURE, 2006, 441 (7090) : 235 - 238
[3] Behcet's disease: evaluation of a new instrument to measure clinical activity
Bhakta, BB
Brennan, P
James, TE
Chamberlain, MA
Noble, BA
Silman, AJ
[J]. RHEUMATOLOGY, 1999, 38 (08) : 728 - 733
[4] Treatment strategies for Behcet's disease
Fresko, Izzet
Yazici, Hasan
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (18) : 3211 - 3219
[5] Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan
Fukuhara, S
Bito, S
Green, J
Hsiao, A
Kurokawa, K
[J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (11) : 1037 - 1044
[6] Cytokine profile in Behcet's disease patients - Relationship with disease activity
Hamzaoui, K
Hamzaoui, A
Guemira, F
Bessioud, M
Hamza, M
Ayed, K
[J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2002, 31 (04) : 205 - 210
[7] Blockade of Interleukin-6 Signaling Suppresses Not Only Th17 but Also Interphotoreceptor Retinoid Binding Protein-Specific Th1 by Promoting Regulatory T Cells in Experimental Autoimmune Uveoretinitis
Haruta, Hiroshi
Ohguro, Nobuyuki
Fujimoto, Minoru
Hohki, Satoshi
Terabe, Fumitaka
Serada, Satoshi
Nomura, Shintaro
Nishida, Kohji
Kishimoto, Tadamitsu
Naka, Tetsuji
[J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2011, 52 (06) : 3264 - 3271
[8] EULAR recommendations for the management of Behcet disease
Hatemi, G.
Silman, A.
Bang, D.
Bodaghi, B.
Chamberlain, A. M.
Gul, A.
Houman, M. H.
Kotter, I.
Olivieri, I.
Salvarani, C.
Sfikakis, P. P.
Siva, A.
Stanford, M. R.
Stuebiger, N.
Yurdakul, S.
Yazici, H.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (12) : 1656 - 1662
[9] Cerebrospinal fluid interleukin-6 in progressive neuro-Behcet's syndrome
Hirohata, S
Isshi, K
Oguchi, H
Ohse, T
Haraoka, H
Takeuchi, A
Hashimoto, T
[J]. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1997, 82 (01): : 12 - 17
[10] STREPTOCOCCAL-RELATED ANTIGENS STIMULATE PRODUCTION OF IL6 AND INTERFERON-GAMMA BY T-CELLS FROM PATIENTS WITH BEHCETS-DISEASE
HIROHATA, S
OKA, H
MIZUSHIMA, Y
[J]. CELLULAR IMMUNOLOGY, 1992, 140 (02) : 410 - 419

← 1 2 3 →